Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure

Margaret P. Chandler, William C. Stanley, Hideaki Morita, George Suzuki, Bridgette A. Roth, Brent Blackburn, Andrew Wolff, Hani N. Sabbah

The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO₂) and thus improves LV mechanical efficiency in dogs with heart failure (HF). Ranolazine did not change MVO₂ and LV mechanical efficiency increased (22.4±2.8% to 30.9±3.4% (P<0.05). In contrast, dobutamine significantly increased MVO₂ and did not improve mechanical efficiency. Thus, short-term treatment with ranolazine improved LV function without an increase in MVO₂, resulting in an increased myocardial mechanical efficiency in dogs with HF.

Free fatty acids (FFAs) are the primary energy substrate of the myocardium; however, they are not as efficient as glucose and lactate. Studies in isolated rat hearts, dogs, pigs, and humans show that external power is reduced for a given myocardial oxygen consumption (MVO₂) when the heart has elevated FFA oxidation. Abnormalities of energy metabolism may contribute to the poor left ventricular (LV) function that characterizes heart failure (HF). Patients with HF designated as New York Heart Association (NYHA) class II–III have greater myocardial FFA oxidation and lower carbohydrate oxidation compared with healthy individuals.

Impaired carbohydrate oxidation may contribute to mechanical dysfunction in the failing heart, as suggested by improved contractile function and efficiency in HF patients when carbohydrate oxidation is stimulated with dichloroacetate or intracoronary pyruvate.

It has been suggested that pharmacological inhibition of myocardial FFA oxidation improves LV function without an increase in MVO₂, and thus increases LV mechanical efficiency. Ranolazine inhibits FFA β-oxidation and significantly improves treadmill time to onset of angina and 1-mm ST-segment depression in patients with chronic stable angina. The purpose of this investigation was to measure MVO₂, LV function, and mechanical efficiency during short-term treatment with ranolazine. We used dobutamine, a positive inotropic agent that should not improve the mechanical efficiency, as a comparator. In addition, the net myocardial uptake of FFAs, glucose, and lactate was assessed.

Materials and Methods

The canine model of chronic HF was previously described in detail. The canine model of chronic HF was previously described in detail. Chronic LV dysfunction and failure were produced by multiple sequential intracoronary embolizations, which results in loss of viable myocardium. Eight healthy dogs (Hodgins Kennel, Howell, Mich) underwent microembolizations to induce HF. This study was approved by the Henry Ford Health System Institutional Animal Care and Use Committee.

Dogs were anesthetized and catheters placed in the femoral vein, coronary sinus, and left ventricle under fluoroscopic guidance, and LV pressure was measured. Cardiac function and coronary flow measurements were made and arterial and coronary sinus (cs) blood samples were analyzed for glucose and lactate in blood and for plasma FFAs.

Calculations

The following calculations were made:

- Stroke volume (SV)=LVEDV-LVESV
- Cardiac output (CO)=stroke volume (SV)×heart rate (HR)
- LV ejection fraction=(LVEDV-LVESV)/LVEDV×100
- Total LV blood flow=((flow velocity×arterial cross-sectional area)×2)¹⁴
- MVO₂=LV blood flow×arterial−cs O₂ difference
- LV power (watts)=(CO) (10⁻⁷ m²/L) (peak LVP) (133.3 Pa/mm Hg)/(60 s/min)
- LV energy expenditure was calculated from MVO₂ assuming 20.2 J/μmol of O₂
- LV mechanical efficiency=LV power/MVO₂

Pretreatment values were compared with posttreatment values using a two-tailed paired Student’s t test with significance set at P<0.05.

Results

Ranolazine and dobutamine increased SV, CO, peak +dP/dt, ejection fraction, and power, without affecting HR or peak LVP. The improvement in LV function with ranolazine was not accompanied by an increase in coronary blood flow or MVO₂ but did result in a significant increase in LV mechanical efficiency (22.4±2.8% to 30.9±3.4%; P<0.05) (Table 1, Figure). In contrast, the improvement in LV function with dobutamine was accompanied by increases in LV power, coronary blood flow, and MVO₂ (33±13% increase in MVO₂), resulting in no change in LV mechanical efficiency (Figure). To determine whether the improvements in cardiac function with ranolazine were specific to the HF state, the effects of ranolazine were assessed in 8 healthy dogs; there were no significant effects on any metabolic or functional measures.
except a small but uniform increase in SV from 33±2 to 35±2 mL (P<0.05).

The net rate of myocardial uptake of FFAs, glucose, and lactate was not affected by treatment with ranolazine in HF. However, dobutamine significantly increased FFA uptake (Table 2).

Discussion

Short-term treatment with ranolazine resulted in greater LV power, no increase in energy expenditure, and greater LV mechanical efficiency in dogs with chronic HF. In comparison, dobutamine increased LV power and energy expenditure and thus did not affect LV mechanical efficiency. Although recent human and animal studies demonstrate that LV mechanical efficiency can be increased in HF by reducing oxidative stress with allopurinol15,16 or biventricular pacing, 17 there are currently no HF therapies aimed specifically at improving LV function and mechanical efficiency through mitochondrial structure, hyperplasia with a reduction of substrate oxidation should be measured using radioisotopes.

Our results do not provide a mechanism for the greater mechanical efficiency observed with ranolazine in HF. Ranolazine is a partial FFA oxidation inhibitor,10 and there is evidence that suppressing FFA oxidation improves LV mechanical efficiency. Theoretically, FFA oxidation requires 25% more oxygen consumption for a given ATP synthesis than glucose or lactate.5 FFAs have been shown to uncouple oxidative phosphorylation,20 cause wasting of O2 by mitochondria,21 and increase the MVO2 for a given LV power. Previously shown in this HF model were severe abnormalities in mitochondrial structure, hyperplasia with a reduction of mitochondrial size,22 and depressed substrate and ADP-stimulated mitochondrial respiration compared with healthy dogs.5 Thus, the improved efficiency with ranolazine is likely attributable to either greater ATP synthesis per O2 consumed and/or more effective ATP use by cardiac cells.

In conclusion, ranolazine improved LV mechanical power without affecting MVO2 and thus resulted in a greater LV mechanical efficiency in dogs with HF. Future studies need to address the effect of long-term treatment with ranolazine on cardiac function, LV remodeling, and clinical outcome.
TABLE 2. Myocardial Glucose, Lactate, and FFA Uptake Before and After Short-Term Treatment With Dobutamine and Ranolazine in Dogs With HF

<table>
<thead>
<tr>
<th></th>
<th>Ranolazine</th>
<th>Dobutamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose uptake, μmol ⋅ min⁻¹</td>
<td>10.0 ± 4.2</td>
<td>13.8 ± 5.4</td>
</tr>
<tr>
<td>Lactate uptake, μmol ⋅ min⁻¹</td>
<td>33.5 ± 7.5</td>
<td>33.4 ± 6.0</td>
</tr>
<tr>
<td>FFA uptake, μmol ⋅ min⁻¹</td>
<td>3.3 ± 0.8</td>
<td>2.8 ± 0.7</td>
</tr>
</tbody>
</table>

*P<0.05, before vs after treatment.

Acknowledgments

This study was supported by National Heart, Lung, and Blood Institute grants HL 49090 (Dr Sabbah) and HL 64848 (Dr Stanley) and a grant from CV Therapeutics, Inc.

References


Key Words: heart failure □ mechanical efficiency □ myocardial metabolism □ fatty acids
Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure
Margaret P. Chandler, William C. Stanley, Hideaki Morita, George Suzuki, Bridgette A. Roth, Brent Blackburn, Andrew Wolff and Hani N. Sabbah

Circ Res. 2002;91:278-280; originally published online July 25, 2002; doi: 10.1161/01.RES.000031151.21145.59
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/91/4/278

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/